



Standard BioTools to Participate in Upcoming Investor Conferences

February 22, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences:

- TD Cowen's 44th Annual Healthcare Conference on Wednesday, March 6, 2024. President and Chief Executive Officer, Michael Egholm, PhD, will present at 1:30 p.m. ET.
- KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024. Egholm will participate in a fireside chat at 10:30 a.m. ET.

Presentations will be webcast live and available on the Investor Relations page of the Company's website at [Events & Presentations](#). A recording will be archived and available on the Standard BioTools Investor Relations page at [investors.standardbio.com](#).

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at [standardbio.com](#) or connect with us on X, Facebook®, LinkedIn and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, "Unleashing tools to accelerate breakthroughs in human health," Imaging Mass Cytometry, IMC, Hyperion, Hyperion XTi and XTi are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information

Standard BioTools uses its website ([standardbio.com](#)), investor site ([investors.standardbio.com](#)), corporate X account (@Standard_BioT), Facebook page ([facebook.com/StandardBioT](#)), and LinkedIn page ([linkedin.com/company/standard-biotools](#)) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools website and its social media accounts in addition to following its press releases, SEC filings, public conference calls and webcasts.

Investor Contact:

David Holmes
ir@standardbio.com



Source: Standard BioTools Inc.